BioSpace News Archive

n-Lorem, a nonprofit foundation , is collaborating with Cytiva in support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients.

Haemonetics Corporation announced that financial results for its third quarter fiscal 2022, which ended January 1, 2022, are available on its Investor Relations website.

AlzeCure Pharma AB announced that it has received a response from the US Food and Drug Administration regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain.

Centogene N.V. today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022.

Cingulate Inc. today announced updates to its 2022 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its third quarter fiscal 2022 key financial results and furnished an update on recent business developments.

Vedere Bio II, Inc., a company developing next-generation therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death, announced the appointment of Martina Schinke, Ph.D., as Vice President, Program Leader.

Cognition Therapeutics, Inc., a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, announced that Anthony Caggiano, M.D., Ph.D., chief medical officer and head of R&D, will participate in a panel discussion during the annual BIO CEO & Investor Conference, entitled, “Exploring the Possibilities of Developing Neurodegenerative Therapeutics.” Joining Dr.

Stealth BioTherapeutics Corp (Nasdaq: MITO), today announced that the company will have an oral presentation at the upcoming 2022 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Soligenix, Inc. announced today that its President and Chief Executive Officer, Christopher J. Schaber , PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022.